Form 4: uniQure Director Sells Shares to Cover Tax Obligations

A director at uniQure N.V. sold 2,112 ordinary shares for $14.45 per share to cover estimated withholding taxes upon the vesting of restricted share units, a non-discretionary transaction.

Summary

• Jeremy P. Springhorn, a Director of uniQure N.V. (QURE), reported a sale of 2,112 ordinary shares.
• The transaction occurred on June 20, 2025.
• The shares were sold at a weighted average price of $14.45 per share, with prices ranging from $14.40 to $14.50.
• The sale was executed solely to cover estimated withholding taxes upon the vesting of restricted share units.
• This was a non-discretionary trade, conducted pursuant to automatic sale instructions.
• Following this transaction, Mr. Springhorn beneficially owns 37,694 ordinary shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale for tax purposes, which does not reflect a change in the insider's view of the company's prospects.

Positives

• The sale was non-discretionary, indicating it was not driven by a change in the director's investment outlook on the company.
• It was a routine transaction to cover tax obligations associated with vested restricted share units.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing indicates that the sale was 'not a discretionary trade by the Reporting Person' and was executed 'solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement.'

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale for tax purposes. Such transactions are common in the biotechnology and pharmaceutical industries, where executive compensation often includes equity awards like restricted share units. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• This filing reports a standard insider transaction (sale for tax withholding) which is a common practice across all industries, including biotechnology. There are no specific comparable companies or projects mentioned in this document to assess against industry standards. The transaction itself is a compliance requirement rather than a performance metric.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the director's direct ownership, but it is a routine tax-related transaction and not indicative of a lack of confidence. The number of shares sold (2,112) is a very small fraction of the company's total outstanding shares, so the direct impact on share price or ownership structure is negligible.

Key Dates

Keywords

uniQure N.V., QURE, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Share Units, Tax Withholding, Director Share Sale